Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 12:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 145,369 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Disorders Clear all

Conditions: Rett Syndrome
Interventions: Dextromethorphan; Drug
Lead sponsor: Hugo W. Moser Research Institute at Kennedy Krieger, Inc.; Other
Eligibility: 2 Years to 15 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Substance Use, Child Abuse, Child Neglect, Fathers, Father-Child Relations
Interventions: Motivational Enhancement, HERO Dads Fatherhood Program, Contingency Management, Case Management; Behavioral
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: Acapatamab, Enzalutamide, Abiraterone, AMG 404; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years · Male only
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 7
States / cities: Birmingham, Alabama • Orange, California • San Francisco, California + 4 more

Conditions: Cardiac Arrhythmias
Interventions: EluPro Antibiotic-Eluting BioEnvelope; Combination Product
Lead sponsor: Elutia Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 4
States / cities: La Jolla, California • Tallahassee, Florida • Boston, Massachusetts + 1 more

Conditions: Coronary Artery Disease
Interventions: Emerge™ 1.20 mm PTCA Dilatation Catheter; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Ulcerative Colitis
Interventions: Tilpisertib, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 23
States / cities: Dothan, Alabama • Lancaster, California • Murrieta, California + 20 more

Conditions: Condyloma
Interventions: Leukocyte Interleukin, Injection 200IU, Leukocyte Interleukin, injection 400IU; Drug
Lead sponsor: United States Naval Medical Center, San Diego; Federal
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: San Diego, California

Conditions: Breast Cancer
Interventions: Crofelemer; Drug
Lead sponsor: Sandra Swain; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland • Hackensack, New Jersey

Conditions: Cocaine Dependence
Interventions: RTI-336 (CTDP 31862); Drug
Lead sponsor: RTI International; Other
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Miramar, Florida

Conditions: Atopic Dermatitis
Interventions: Caffeine, Metoprolol, Midazolam, Warfarin, Vitamin K, Omeprazole, Rocatinlimab; Dietary Supplement · Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 7
States / cities: North Hollywood, California • DeLand, Florida • Hialeah, Florida + 4 more

Conditions: Glioblastoma Multiforme, Anaplastic Astrocytoma, Gliosarcoma
Interventions: M032, Pembrolizumab; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Colorectal Cancer, Colorectal Neoplasms, Health Screening
Interventions: Active FIT Choice, Active Colonoscopy Choice, Active Dual Choice; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 45 Years to 49 Years
Enrollment: 20,509 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 2
States / cities: Los Angeles, California • Westwood, Los Angeles, California

Conditions: Obsessive-Compulsive Disorder
Interventions: Tolcapone 200 MG; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: UC (Urothelial Cancer)
Interventions: Pembrolizumab, Epacadostat, Placebo; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 22
States / cities: Tucson, Arizona • Orange, California • New Haven, Connecticut + 16 more

Conditions: Non-small Cell Lung Cancer (NSCLC) With Brain Metastases
Interventions: GRN1005; Drug
Lead sponsor: Angiochem Inc; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 9
States / cities: La Jolla, California • Aurora, Colorado • Tampa, Florida + 6 more

Conditions: Osteoporosis, Multiple Myeloma
Interventions: Romosozumab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Aphasia
Interventions: Visual Feedback Training; Behavioral
Lead sponsor: The University of Texas at Dallas; Other
Eligibility: 21 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 3
States / cities: Irvine, California • Columbia, South Carolina • Richardson, Texas

Conditions: Depression
Interventions: Sertraline, Placebo, BupropionXL; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 296 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2016
U.S. locations: 4
States / cities: Boston, Massachusetts • Ann Arbor, Michigan • New York, New York + 1 more

Conditions: Gastric Antral Vascular Ectasia
Interventions: Radiofrequency ablation; Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 100 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: COPD, COPD Exacerbation
Interventions: mHealth Intervention; Other
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 18 Years to 100 Years
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Graft Versus Host Disease
Interventions: beclomethasone dipropionate; Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 4 Years to 70 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Graft vs Host Disease, Graft-Versus-Host Disease
Interventions: Pomalidomide; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Autism Disorder, Language Development Disorders, ADHD, Typical Development, Rural Health, Children, Neuroimaging, Eye Tracking, EEG, fNIRS
Interventions: Speech-Gesture combinations; Behavioral
Lead sponsor: Montana State University; Other
Eligibility: 2 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Bozeman, Montana

Conditions: Infections, Meningococcal
Interventions: Meningococcal vaccine GSK134612; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 2 Years to 6 Years
Enrollment: 387 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2014
U.S. locations: 14
States / cities: Benton, Arkansas • Little Rock, Arkansas • Antioch, California + 10 more

Search by objective public record fields.

Trial of Dextromethorphan in Rett Syndrome

A Regional Partnership to Improve Outcomes Through Fatherhood Engagement

Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)

EluPro Antibiotic-Eluting BioEnvelope Registry

Evaluation of Coronary Luminal Diameter Enlargement With Emerge™ 1.20 mm PTCA Dilatation Catheter

Study to Evaluate the Efficacy and Safety of Tilpisertib in Adults With Moderately to Severely Active Ulcerative Colitis

Safety Study of Multikine in the Treatment of Perianal Warts

Diarrhea Prevention and Prophylaxis With Crofelemer in HER2 Positive Breast Cancer Patients

Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of RTI-336 in Healthy, Male Subjects

Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis

Study of Pembrolizumab and M032 (NSC 733972)

The Impact of Choice on Colorectal Cancer Screening

Tolcapone in Obsessive Compulsive Disorder

Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)

GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L)

A Study of Romosozumab in Women With Multiple Myeloma and Osteoporosis

Neural Bases of Vocal Sensorimotor Impairment in Aphasia

Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care for Depression

Prospective Evaluation Of Outcomes For Patients Undergoing Radiofrequency Ablation (RFA) Using HALO Ultra Device For Gastric Antral Vascular Ectasia (GAVE)

Using Mobile Health to Respond Early to Acute Exacerbations of COPD in HIV

Compassionate Use of Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Gastrointestinal Tract

Pomalidomide for Chronic Graft-versus-Host Disease

Rural Autistic Individuals - Supporting Expression

The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Toddlers